Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis

被引：0
|
作者：
Spadaro, A. [1 ]
Scarno, A. [1 ]
Carboni, A. [1 ]
Perrotta, F. M. [1 ]
Catalano, C. [2 ]
Lubrano, E. [3 ]
Valesini, G. [1 ]
机构：
[1] Univ Roma La Sapienza, UOC Reumatol, Dipartimento Med Interna & Specialita Med, Rome, Italy
[2] Univ Roma La Sapienza, Radiol Cent UOC A, Dipartimento Med Mol, Rome, Italy
[3] Univ Molise, Dipartimento Med & Sci Salute, Campobasso, Italy
来源：
REUMATISMO | 2013年 / 65卷 / 03期
关键词：
Certolizumab pegol; Axial spondyloarthritis; Magnetic resonance;
D O I：
10.4081/reumatismo.2013.134
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.
引用
收藏
页码：134 / 137
页数：4
相关论文
共 50 条
  • [1] Certolizumab Pegol Effectiveness in Radiographic and Non-Radiographic Axial Spondyloarthritis. a Natiowide Study
    Gonzalez, Carlos M.
    Exposito, Rosa
    Garcia-Portales, Rosa
    Urruticoechea-Arana, Ana
    Ramon Lamua, Jose
    del Pilar Navarro, Maria
    Rey Rey, Jose Santos
    Fernandez, Manuel
    Morcillo, Mercedes
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [2] Earlier treatment of non-radiographic axial spondyloarthritis with certolizumab pegol results in improved clinical outcomes
    Rudwaleit, M.
    Gensler, L. S.
    Deodhar, A.
    Kay, J.
    Maksymowych, W. P.
    Haroon, N.
    Landewe, R.
    Auteri, S. E.
    de Peyrecave, N.
    Kumke, T.
    Hoepken, B.
    van der Heijde, D.
    [J]. SWISS MEDICAL WEEKLY, 2019, : 17S - 17S
  • [3] EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES
    Rudwaleit, Martin
    Gensler, Lianne S.
    Deodhar, Atul
    Kay, Jonathan
    Maksymowych, Walter P.
    Haroon, Nigil
    Landewe, Robert B. M.
    Auteri, Simone
    de Peyrecave, Natasha
    Kumke, Thomas
    van der Heijde, Desiree
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 891 - 891
  • [4] Effect Of Certolizumab Pegol Over 48 Weeks In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
    Landewe, Robert B. M.
    Rudwaleit, Martin
    van der Heijde, Desiree M.
    Dougados, Maxime
    Mease, Philip J.
    Reveille, John D.
    Walsh, Jessica
    Kivitz, Alan J.
    Maksymowych, Walter P.
    Braun, Juergen
    Deodhar, Atul A.
    Stach, Christian
    Hoepken, Bengt
    Singh, Pritibha
    Sieper, Joachim
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S767 - S767
  • [5] Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
    Maksymowych, Walter
    Landewe, Robert
    Rudwaleit, Martin
    van der Heijde, Desiree
    Dougados, Maxime
    Mease, Phillip
    Reveille, John
    Walsh, Jessica
    Kivitz, Alan
    Braun, Juergen
    Deodhar, Atul
    Stach, Christian
    Hoepken, Bengt
    Singh, Pritibha
    Sieper, Joachim
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1496 - 1497
  • [6] Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
    Deodhar, Atul A.
    Dougados, Maxime
    Landewe, Robert
    Sieper, Joachim
    Maksymowych, Walter
    Rudwaleit, Martin
    van Den Bosch, Filip
    Braun, Juergen
    Mease, Philip J.
    Kivitz, Alan
    Walsh, Jessica
    Davies, Owen
    Hoepken, Bengt
    Peterson, Luke
    van der Heijde, Desiree
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] COST ANALYSIS OF WORK AND HOUSEHOLD PRODUCTIVITY IMPROVEMENTS WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN SPAIN
    Ferrando, R.
    Echave, M.
    Espinoza Camac, N.
    Maratia, S.
    Casado, M. A.
    [J]. VALUE IN HEALTH, 2020, 23 : S596 - S596
  • [8] Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis.
    Sieper, Joachim
    Rudwaleit, Martin
    van der Heijde, Desiree M.
    Maksymowych, Walter P.
    Dougados, Maxime
    Mease, Philip
    Braun, Juergen
    Deodhar, Atul A.
    Hoepken, Bengt
    Nurminen, Tommi
    Landewe, Robert B. M.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S376 - S377
  • [9] PREDICTORS OF RESPONSE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING CERTOLIZUMAB PEGOL IN THE C-AXSPAND STUDY
    Maksymowych, W. P.
    Kumke, T.
    Auteri, S.
    Hoepken, B.
    Bauer, L.
    Rudwaleit, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 704 - 705
  • [10] Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol
    Maksymowych, Walter P.
    Kumke, Thomas
    Auteri, Simone E.
    Hoepken, Bengt
    Bauer, Lars
    Rudwaleit, Martin
    [J]. ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
12345